Skip to main content

Table 4 Tumor response to 2nd EGFR-TKI vs. chemotherapy

From: Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis

Characteristics 2nd TKI group Control group P
OS from 1st gefitinib   
   Median 21.5 12.3 0.07
   95% CI 14.6 - 28.4 9.4 - 15.2  
Response to 2nd TKI or chemotherapy  
   PR 1 0  
   SD 7 1  
   PD 3 4  
PFS to 2nd TKI or chemotherapy   
   Median 3.4 2 0.1
   95% CI 2 - 5.2 1.5 - 2.4  
OS from 2nd TKI or chemotherapy   
   Median 7.3 2.2 0.12
   95% CI 2.7 - 13 2.2 - 2.8